Tax regulations

Chevron Corp. used a shell company in a tax haven to escape hundreds of millions of dollars in Australian taxes, according to a 2015 court ruling. The subsidiary, which allowed Chevron to eliminate Australian taxes on $1.7 billion in profit earned there, wasn’t secreted away on a remote tropical island—it was set up in the very mundane locale where corporate secrecy was born: Delaware.

The Internal Revenue Service has released final regulations providing guidance to private foundations on program-related investments.

A senior Treasury Department official in charge of international tax policy is seeing a greater role being played by the Group of 20 finance ministers in setting the agenda for tax laws around the world.

Payroll tax credits, workforce training grants, infrastructure grants, property tax abatements and tax increment financing are just a few of the tools that state and local economic development groups have at their disposal to entice businesses to expand and invest in their communities.

The Senate Finance Committee has dropped a provision for regulating tax preparers from legislation that would curb identity theft and tax fraud.

Why would anyone spend $24 million to buy a 1 percent stake in the New York Yankees? Minority ownership seems like a lose-lose proposition: A lot of money for very little power. For wealthy sports fans, though, it’s cool—and can be one heck of a tax shelter.

European Union regulators sought to shame big global companies into paying their full tax bill by forcing them to publish how much they divert to offshore havens.

Escalating a 19-month regulatory assault against U.S. companies’ shifting their tax addresses offshore, President Barack Obama’s administration last week also went after companies that have always been overseas.

Among the issues that are keeping tax executives up at night are anti-inversion rules that don’t address the root cause: an anti-competitive U.S. tax system.

The White House traded accusations of unpatriotic behavior with the CEO of a major drugmaker after unexpectedly tough new rules from the U.S. Treasury Department on corporate inversions derailed a $160 billion merger between Pfizer Inc. and Allergan Plc.